Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Tvardi Therapeutics (TVRD) Gross Margin (2022 - 2024)

Tvardi Therapeutics' Gross Margin history spans 3 years, with the latest figure at 100.0% for Q4 2024.

  • On a quarterly basis, Gross Margin rose 2024.0% to 100.0% in Q4 2024 year-over-year; TTM through Dec 2024 was 91.31%, a 2076.0% increase, with the full-year FY2024 number at 91.31%, up 2076.0% from a year prior.
  • Gross Margin hit 100.0% in Q4 2024 for Tvardi Therapeutics, roughly flat from 100.0% in the prior quarter.
  • Over the last five years, Gross Margin for TVRD hit a ceiling of 100.0% in Q2 2022 and a floor of 34.68% in Q4 2022.
  • Historically, Gross Margin has averaged 76.6% across 3 years, with a median of 75.65% in 2022.
  • The widest YoY moves for Gross Margin: up 4508bps in 2023, down -2045bps in 2023.
  • Tracing TVRD's Gross Margin over 3 years: stood at 34.68% in 2022, then soared by 130bps to 79.76% in 2023, then rose by 25bps to 100.0% in 2024.
  • Business Quant data shows Gross Margin for TVRD at 100.0% in Q4 2024, 100.0% in Q3 2024, and 100.0% in Q2 2024.